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BACKGROUND: Oral submucous fibrosis (OSF) is a
chronic progressive disease of the oral cavity that is
considered a common potentially malignant disorder in
South Asia. Areca nut chewing is the main etiological
factor, but its carcinogenic mechanism has yet to be
proven. The purpose of this study was to identify the
useful biomarkers in predicting high-risk patients with
OSF.
METHODS: Thirty-six cases of OSF and six cases of
normal oral mucosa (NOM) were used for this study.
Immunohistochemical staining was performed for Ki67,
cyclin D1, p16, p53, b-catenin, c-Jun, c-Met, and insulin-
like growth factor II mRNA-binding protein 3 (IMP3). The
expression patterns of NOM served as guidelines for the
scoring system.
RESULTS: The expression of Ki67, cyclin D1, c-Met,
IMP3, and b-catenin showed a significant difference
between OSF and NOM samples. The combined
biomarkers of Ki67 and p16 showed significantly different
expression between the transformation and non-trans-
formation groups. With discriminant analysis, we pro-
posed a noble formula and cutoff value for predicting
high-risk patients with OSF.
CONCLUSION: The notable biomarkers in our present
study were Ki67 and p16 showing significantly different
expression levels between the transformation and non-
transformation groups. With the identification of high-
risk patients with OSF, we can expect to develop more
intensive treatment modalities, leading to the reduction
in cancer transformation rate from OSF.
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Introduction
Oral submucous ﬁbrosis (OSF) is a chronic progressive oral
mucosal disease with a potential for malignant transforma-
tion (1). Clinical presentation depends on the stage of the
disease. Initially, most patients present with a burning
sensation or intolerance to spicy food, and they may have
vesicles, particularly on the palate. Ulceration and dryness
of the mouth are later followed by ﬁbrosis of the oral
mucosa, leading to rigidity of the lips, tongue, and palate
and causing trismus (2). The important histopathologic
features consist of the deposition of dense collagen in the
lamina propria associated with epithelial atrophy. Initially,
there is juxta-epithelial inﬂammation followed by hyalin-
ization (3). OSF is frequently noted in South-East Asian
countries where areca nut chewing is popular, suggesting
that this habit is the most important etiological factor in the
pathogenesis of OSF (4).
Importantly, the malignant transformation rate was shown
to be 7.6% over a period of 17 years (5, 6). Furthermore,
more than 2400 new cases of oral squamous cell carcinoma
(OSCC) arising from OSF have been diagnosed each year in
Taiwan due to the prevalent use of betel quid (5). Therefore,
the early detection of potentially malignant OSF has been
crucial in the inhibition of oral cancer.
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Many efforts have been made to explore carcinogenesis
and identify predictable diagnostic biomarkers in OSF.
However, no useful marker has been identiﬁed to date. To
identify the useful biomarkers in predicting oral cancer
development in patients with OSF, we performed immuno-
histochemical staining for eight candidate biomarkers. Every
biomarker has its own special attribution to be selected.
Ki67 and cyclin D1 can be used to evaluate the cell
proliferation (7). p16 and p53 were investigated as tumor-
suppressor genes known to be affected in head-and-neck
squamous cell carcinomas (HNSCCs). In HNSCCs, the
incidence of p16 inactivation due to mutation was reported
to be 10% (8) and that by homozygous deletion was 33%
(9). Thus, point mutations in p53 occur in 10–17% of
precancerous disease and in 35–67% of OSCC (10). To
further investigate the transcriptional activity in OSF tissue,
the expression levels of b-catenin and c-Jun were evaluated
(11, 12). Growth factor receptors c-Met and insulin-like
growth factor II mRNA-binding protein 3 (IMP3) were
reported to play pivotal roles in tumor invasion (13, 14).
The aim of our study was to generate a prediction model
for risk assessment using combined biomarkers. Although
no single biomarker has been satisfactory in predicting
carcinomatous transformation of potentially malignant OSF,
the combined biomarkers identiﬁed in our study may be
clinically useful to detect high-risk OSF and reduce the
incidence of OSCC, thus guiding the clinician’s decision on
the diagnosis, treatment, and prevention strategies.
Materials and methods
Human tissue samples
Thirty-six formalin-ﬁxed, parafﬁn-embedded biopsy speci-
mens with clinically and pathologically conﬁrmed OSF
were obtained from the Department of Oral Pathology,
Faculty of Dental Sciences, University of Peradeniya, Sri
Lanka (Table 1). Six samples of normal oral mucosa
(NOM) were used as controls. The study has been approved
by an ethical committee from the Institutional Research
Board of the Faculty of Dental Sciences, University of
Peradeniya, Sri Lanka (No: FDS-FRC/2014/18).
Hematoxylin and eosin staining
Formalin-ﬁxed, parafﬁn-embedded specimens were cut into
4-lm-thick sections and were stained with hematoxylin and
eosin for histologic conﬁrmation of clinical diagnosis and to
grade epithelial dysplasia. Additional sequential sections
were prepared for immunohistochemical studies.
Immunohistochemistry protocol
All 36 cases of OSF were available for high-quality
immunohistochemical staining except one tissue sample in
which epithelial tissue was lost for p53 staining. Immuno-
histochemical stainingwas performed on 4-lm-thick sections
using an EnVision-HRP detection system (Dako, Carpinteria,
CA, USA). All of the procedures were performed at room
temperature. The sections were deparafﬁnized through a
series of xylene baths and rehydrated in graded concentra-
tions of alcohol. To retrieve antigenicity, the slides were
steamed with 10 mM citrate buffer (pH 6.0; Dako REALTM).
Tissue sections were treated with 3% hydrogen peroxide to
block endogenous peroxidase activity, followed by incuba-
tion in 5% bovine serum albumin. The sections were then
incubated with primary antibodies diluted with phosphate-
buffered saline for 90 min in a humid chamber. The dilution
ratio of each antibody is as follows: Ki67, p53, and c-Jun
were used in 1:100, cyclin D1 in 1:400, IMP3 in 1:50, and b-
catenin in 1:80, respectively, which were purchased from
Abcam (Cambridge, UK); p16 and c-Met were used in 1:50
and 1:200, respectively, which were purchased from (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
The slides were then incubated with secondary EnVision
reagent (Dako, Carpinteria, CA, USA) for 30 min, followed
by incubation with 3,3-diaminobenzidine tetrachloride
(Dako). Next, the sections were counterstained with
Mayer’s hematoxylin for visualization. The dilution solution
without antibody treatment was applied as the negative
control. The expression pattern of OSF was compared with
that of NOM.
Scoring system
Immunostained sections for all antibodies were indepen-
dently studied in detail by three oral pathologists, and the
tissue sections were graded as follows:
The expression patterns ofNOMserved as guidelines for the
scoring system. The scoring methods were deﬁned based on
different criteria for each antibodydepending on the expression
pattern and cellular localization of NOM. The expression was
scored from0 to 3. The expression pattern ofNOMwas given a
score 1. Score 0 represented a lower expression than that of
NOM; Score 1 represented the same expression pattern as
NOM; Score 2 or 3 represented higher expression than that of
NOM. The scoring criteria are shown in Table 2.
Statistical analysis
Correlation between the clinical ﬁndings of patients and
cancer risk was analyzed by Fisher’s exact test. We applied
Fisher’s exact test to compare the biomarkers determining
between NOM and OSF, between the absence and presence
of epithelial dysplasia and between cancerous transforma-
tion and non-transformation OSFs. Furthermore, discrimi-
nant analysis was used to identify a combined biomarker
Table 1 Clinical information of patients
Parameters
No. of patients
(N = 36)
Without
transforma-
tion to
cancer
With
transfor-
mation to
cancer
No. % No. %
Sex
Female 12 9 29 3 60
Male 24 22 71 2 40
Age (years)
<50 22 19 61.2 3 60
≥50 14 12 38.8 2 40
Tumor site
Buccal mucosa 32 28 90.4 4 80
Lip 2 1 3.2 1 20
Tongue 1 1 3.2
Undeﬁned 1 1 3.2
Histology
With dysplasia 12 9 29 3 60
Without dysplasia 24 22 71 2 40
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model. The expression of combined biomarker was com-
pared between cancerous transformation and non-transfor-
mation samples by Mann–Whitney U-test. All of the
statistical analyses were performed using statistical software
(SPSS ver. 21.0; SPSS Inc., Chicago, IL, USA), and the
level of statistical signiﬁcance was set at P < 0.05.
Results
Characteristics of the patients and oral cancer risk
The medium follow-up period for the patient population was
6.5 years, with ﬁve (13.8%) of 36 patients transformed to
invasive carcinoma. The clinicopathological characteristics
of the patients are listed in Table 1.
Of 12 cases showing epithelial dysplasia, three were
transformed to invasive carcinoma. Using statistical analy-
sis, neither any clinical factor nor the presence of epithelial
dysplasia was related to cancerous transformation (data not
shown).
Biomarkers for determining NOM and OSF
To identify the biomarkers to differentiate between OSF
and NOM, we used Fisher’s exact test. The expression of
Ki67, cyclin D1, c-Met, IMP3, and b-catenin showed a
signiﬁcant difference in the OSF, as compared with the
NOM (Table 3 and Fig. 1). To examine the proliferating
activity, positive cells for Ki67 and cyclin D1 were
counted, and the proliferation index was measured by
calculating the percentage of positive cells from the total
number of cells. The proliferating indices of cyclin D1 and
Ki67 were 4–9% and 2–8% in the NOM, respectively. In
contrast, most cases of OSF showed no positive reaction
for both biomarkers with the exception that Ki67 expres-
sion was found to be increased in OSF cases with
malignant transformation (Fig. 1C). The expression of
c-Met and IMP3 showed higher expression in the OSF
than in the NOM showing undetectable and weak
expression (Fig. 1G–L), whereas b-catenin showed
reduced expression in the OSF, as compared with the
NOM (Fig. 1M–O).
Correlation between biomarker expression and epithelial
dysplasia
The correlation between the expression of biomarkers and
histologic status is shown in Table 3. The biomarkers of
p53 and p16 were found to be positively related to epithelial
dysplasia in the OSF (P = 0.00 and P = 0.04, respectively).
p53 expression showed no positive response in the NOM
(Fig. 2D). By contrast, p53 overexpression was found in six
of 12 dysplastic samples, regardless of malignant transfor-
mation (Fig. 2E,F). p16 expression showed the positivity of
less than 5% in the epithelium of NOM samples (Fig. 2A).
p16 showed both nuclear and cytoplasmic expression in
OSF samples. Particularly, two of three cases of malignant
transformed OSF with epithelial dysplasia revealed high p16
expression scored as 2 (Fig. 2C).
Table 2 Evaluation criteria of expression patterns of immunohistochemical staining
Biomarkers 0 1 2 3
Ki67 Negative or less than NOM 2–8% immunoreactive cells in NOM More than 8% –
Cyclin D1 Negative or less than NOM 4–9% immunoreactive cells in NOM – –
p16 – 0–5% cytoplasmic and nucleus
immunoreactive cells in NOM
More than 5% –
IMP3 – Less than 30% of epithelial cells
with cytoplasmic and perinuclear
immunoreactivity in NOM
30–60% of epithelial
cells with cytoplasmic
and perinuclear
immunoreactivity
in NOM
More than 60% epithelial with
cytoplasmic and perinuclear
immunoreactivity in NOM
b-Catenin Positive cells found less than
50% of epithelium
membranous immunoreactivity
50–100% membranous
immunoreactivity in NOM
– –
p53 – No expression in NOM Nucleus expression in
basal cell layer of
epithelium
–
c-Met – No expression in NOM Cytoplasmic expression
in basal and suprabasal
layer of epithelium
–
c-Jun Negative Suprabasal area nuclear
expression in NOM
Nucleus expression
cells in basal cell layer
–
NOM, normal oral mucosa.
Table 3 Statistical analysis according to differently expressed gene in
tissue groups
Biomarkers
expression
pattern
Comparison
between NOM
and OSF
Comparison
between with
and without
dysplasia
Comparison
between with
and without
transformation to cancer
Ki67 0.00 0.30 0.02
Cyclin D1 0.00 0.60 0.40
c-Met 0.01 0.24 0.03
IMP3 0.00 0.27 0.34
b-Catenin 0.02 1.00 0.63
c-Jun 0.90 0.79 0.56
p16 0.55 0.04 0.00
p53 0.19 0.00 0.87
NOM, normal oral mucosa; OSF, oral submucous ﬁbrosis; IMP3, insulin-
like growth factor II mRNA-binding protein 3.
P values from Fisher’s exact test are provided.
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Ki67 Ki67 Ki67
Cyclin D1 Cyclin D1 Cyclin D1
c-Met c-Met c-Met
ß-catenin ß-catenin ß-catenin
IMP3 IMP3 IMP3
A B C
D E F
G H I
J K L
M N O
Figure 1 Immunohistochemical expression pattern for each antibody in the normal oral mucosa group (A, D, G, J, M); Oral submucous ﬁbrosis (OSF)
samples without cancer transformation (B, E, H, K, N); OSF samples with cancer transformation (C, F, I, L, O). Ki67 (A–C); the dark brown nuclear staining
was considered to be positive for Ki67. Ki67 expression reduced in OSF samples without cancer transformation (B), whereas its positivity increased in OSF
samples with cancer transformation (C). Cyclin D1 expression (D–F) was reduced in both OSF samples with and without cancer transformation. c-Met
expression (G–I) increased in OSF samples with cancer transformation. IMP3 expression (J–L) increased in both OSF samples with and without cancer
transformation. b-Catenin expression (M–O) reduced in OSF samples with and without cancer transformation. The original magniﬁcation of all ﬁgures was
taken at 9200. Higher magniﬁcation (91000) views of Ki67 expression are presented in the inset micrograph (scale bar of all ﬁgures, 50 lm).
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Biomarkers for determining cancerous transformed and
non-transformed OSFs
According to the Fisher’s exact test, Ki67, c-Met, and p16
were the most useful biomarkers to determine high-risk OSF
(P = 0.02, P = 0.03, and P = 0.00, respectively) (Table 3).
As described, NOM showed 2–8% of positive activity by
Ki67 expression (Fig. 1A). In contrast, 26 (83.9%) of 31
OSF samples without malignant transformation showed
negative to markedly reduced expression (Fig. 1B). Of ﬁve
OSF samples with transformation, two (40%) were scored
as 0 and two (40%) were scored as 1. A single case was
scored as 2 showing an increased proliferating activity
compared with NOM cases (Fig. 1C).
c-Met expression was undetectable in the NOM
(Fig. 1G). Sixteen (51.6%) of 31 OSF samples without
transformation exhibited the same expression pattern as that
of the NOM and were scored as 1 (Fig. 1H). In contrast, all
cases of OSF with transformation showed a deﬁnite
cytoplasmic staining in the basal and suprabasal layers
and were scored as 2 (Fig. 1I).
p16-positive cells were observed in less than 5% of all
epithelium with nuclear and cytoplasmic immunoreactivity
in the NOM (Fig. 2A). Surprisingly, all 31 (100%) OSF
samples without transformation were observed to have the
same expression as NOM and were scored as 1 (Fig. 2B). In
contrast, the same expression as NOM was found in three
samples (60%) of OSF with transformation, and they were
scored as 1. The higher expression was detected in two
(40%) OSF samples with transformation than in the NOM
and was scored as 2 (Fig. 2C).
Combined biomarker model to predict high-risk OSF
To improve the prognostic predictability of the biomarkers,
we used the combined biomarker model. By discriminant
analysis, the combination of the Ki67 and p16 biomarkers
was identiﬁed to show the highest predictability. The
combined expression levels were calculated as
0.688 9 Ki67 + 0.888 9 p16, and they were signiﬁcantly
different between the groups (P = 0.00108). The combined
expression levels were distributed as shown in Fig. 3, and
c-Jun c-Jun
p53 p53 p53
p16 p16 p16
c-Jun
A B C
D E F
G H I
Figure 2 Immunohistochemical expression pattern for each antibody in the normal oral mucosa (NOM) group (A, D, G); Oral submucous ﬁbrosis (OSF)
samples without cancer transformation (B, E, H); OSF samples with cancer transformation (C, F, I). p16 expression (A–C) increased in dysplastic OSF
samples with cancer transformation (C). p53 expression (D–F) showed no response in NOM samples (D). OSF samples with dysplasia showed a positive
reaction regardless of cancer transformation (E, F). c-Jun expression (G–I) showed no difference between OSF samples with and without cancer
transformation (original magniﬁcation, 9200; magniﬁcation of inset micrographs, 91000; scale bar of all ﬁgures, 50 lm).
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they could be classiﬁed into high- and low-risk groups
based on the cutoff value of 0.9. Furthermore, the predictive
accuracy was 94.4%. The sensitivity and speciﬁcity were
0.6 and 1, respectively.
Discussion
Recent epidemiological data indicate that the OSF preva-
lence has increased since 2000 (2.42 in 2000 to 6.42/1000/
year in 2004) (15). One study recognized that OSCC
originating from OSF is clinically more invasive and also
exhibits a higher metastasis and recurrence rate than OSCC
not originating from OSF (16). Therefore, there has been
much focus on investigating biomarkers for the prevention
and early detection of carcinomatous transformation. In this
study, we examined several biomarkers to investigate the
useful biomarkers in predicting oral cancer development in
patients with OSF. The selection of biomarkers was based
on the understanding of the physiological/pathological
features of OSF tissue. For detecting clinically feasible
biomarkers in the routine diagnostic level, this study did not
include DNA-targeting methods such as DNA aneuploidy,
but it was conﬁned to examine the protein expression by
immunohistochemical staining.
We have observed that Ki67, cyclin D1, c-Met, IMP3,
and b-catenin were found to show signiﬁcantly different
expression between the NOM and the OSF. All of these
biomarkers have gained attention as prognostic biomarkers
to predict the proliferation activity and transcriptional
activity, as indicators for metastasis and poor prognosis
and as good targets for therapeutic inhibition. Ki67 and
cyclin D1 were used to evaluate the cell proliferation. Ki67
is a nuclear marker expressed in all phases of the cell cycle
other than the G0 phase and is widely used as a surrogate
marker for proliferation in tumor samples (17, 18). Cyclin
D1 modulates cell cycle transition from G1 to S phase and
also plays a role in apoptosis (19). In our study, proliferating
activity was found to be reduced in OSF samples compared
with the NOM through the expression of cyclin D1 and
Ki67. Contradictory results to our study were found by the
research group of Ranganathan and Kavitha (20) observing
that Ki67 expression in the OSF was signiﬁcantly higher
than that of NOM, but less than that of OSCC. This different
result may be explained as the proliferating activity of the
OSF being largely dependent on the developmental stage.
The OSF at the early stage may show a lower proliferating
activity, as evidenced by atrophic epithelium. In our study,
the proliferation activity of OSF samples with cancerous
transformation showed higher proliferating activity than that
of the NOM and OSF samples without transformation,
suggesting that the switch toward the upregulation of the
cell cycle from atrophic epithelium could represent trans-
formation.
Recent studies have shown that IMP3 is an important
protein for tumor cell proliferation and invasion, indicating
that IMP3 is an oncofetal protein that may play a critical
role in malignant transformation and tumor progression
(21). IMP3 was found to be expressed in carcinoma lesions
and oral leukoplakia with dysplasia (22). Previous studies
have suggested that the IMP3 staining pattern should be a
useful adjunct in distinguishing benign from malignant
squamous epithelia. In our study, IMP3 expression
increased in the OSF compared with the NOM, whereas
we could not ﬁnd a clear relationship with malignant
transformation or epithelial dysplasia. c-Met plays a crucial
role in morphogenic organization during embryonic devel-
opment and in the control of the structure and function of
adult tissues, including cell migration and proliferation
necessary for injury repair (23). Speciﬁcally, a signiﬁcant
increase in the expression of c-Met was noted in the
transformation from NOM to epithelial dysplasia and to
OSCC (24). In our study, both IMP3 and c-Met were found
to show higher expression in OSF samples than in NOM
samples, suggesting that these two proteins may play roles
in developing OSF. In addition, b-catenin signaling has
been implicated in promoting many human squamous cell
carcinomas (25). b-Catenin expression was reported to show
reduced expression in OSCC (26). In our study, we found
the reduced expression of b-catenin in OSF samples,
reﬂecting the disruption of the E-cadherin–catenin complex.
Taken together, the insulted epithelium by carcinogens,
such as areca nut, undergoes genetic alterations, as
evidenced by the increased expression of IMP3 and c-Met
and reduced expression of b-catenin.
Notable biomarkers in our present study were Ki67 and
p16, which showed signiﬁcantly different expression
between the transformation and non-transformation OSFs.
According to the discriminant analysis, the combination of
Ki67 and p16 was identiﬁed to show the highest pre-
dictability for high-risk OSF. Co-expression of both proteins
was determined as the combined biomarker model
(P = 0.00108). Accordingly, we propose that these two
markers may play a role in predicting malignant transfor-
mation and could be used as biomarkers for high-risk OSF.
p16 represents a negative regulator of the cell cycle that
ensures the control of the cellular passage from G1 phase to
S phase. Mitogenic stimuli, as well as growth factors,
determine the activation of cyclin D, resulting in retinoblas-
toma protein phosphorylation, followed by the release of a
transcription factor that ensures cell proliferation (27). The
relationship between p16 expression and its biologic
behavior has been debatable, although the relationship
between human papillomavirus infection and p16 expres-
sion has been highly correlated (28). In our study, we
demonstrated that p16 positivity could provide evidence for
Figure 3 Results of discriminant analysis, Ki67 and p16 were identiﬁed
as combined biomarkers for the high-risk oral submucous ﬁbrosis groups.
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assessing high-risk OSF. Taken together, the proliferating
activity of more than 8% and p16 expression of more than
5% can serve as promising biomarkers to assess the high
risk of OSF. Furthermore, the proposed formula and cutoff
value is the ﬁrst trial to predict risk assessment using
combined biomarkers in potentially malignant OSF. With
the identiﬁcation of high-risk patients with OSF, more
intensive treatment modalities can be developed, resulting in
a reduced incidence of OSCC.
The positive relationship between epithelial dysplasia and
malignant transformation in OSF has been investigated (29).
In our study, we could not ﬁnd the positive correlation
between epithelial dysplasia and malignant transformation
in OSF. This discrepancy can be explained by insufﬁcient
number of the study samples and the subjectivity of
determining epithelial dysplasia.
Limitations of our current study might be considered as
follows. First, only ﬁve cases in the OSF with malignant
transformation were enrolled in this study. To conﬁrm our
data, a prospective clinical study should be conducted.
Second, with regard to the multistep carcinogenic process,
protein expression may peak at different stages proven by
sequential expression of p53 during transformation from
precancer to cancer (30). Considering the dynamic process
of human disease state, our prediction model with proposed
formula should be validated by large-scale studies. Third,
this study did not detect human papillomavirus infection in
OSF cases. Further study of the observing expression
pattern of markers according to human papillomavirus
infection in OSF may contribute to the consolidation of our
results for clinical application.
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